- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01471795
The Epidemiology of Ventricular Assist Device-Related Infections
Study Overview
Status
Conditions
Detailed Description
Infections are one of the most serious of ventricular assist device (VAD) related complications. Many of these infections are associated with significant patient morbidity and mortality. Diagnosis of these infections is often difficult due to the complicated nature of the patient's medical problems, the need for rapid institution of empiric antibiotic therapy and the lack of established criteria that define infection. Staphylococci are among the most common causes of VAD infections. The basis for this high incidence is not well understood but is believed to be in part due to inoculation of staphylococcal commensal flora into wound sites at the time of surgery or thereafter. The goals of this observational study are to develop a better understanding of the pathogenesis and epidemiology of Staphylococcus aureus and epidermidis-VAD infections as well as to develop a set of criteria that can be used to help diagnose the presence or absence of a VAD related infection.
This is a prospective, multi-center, observational study to identify risk factors associated with the development of VAD-related infections. Patients will be followed for up to one year following VAD implantation, time of death or transplantation, whichever comes first. There will be no randomization for this observational study.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
California
-
San Diego, California, United States, 92123
- Sharp Memorial Hospital
-
-
Illinois
-
Oak Lawn, Illinois, United States, 60453
- Advocate Christ Medical Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Jewish Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
New York, New York, United States, 10032
- Columbia Presbyterian Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
-
Utah
-
Salt Lake City, Utah, United States, 84143
- LDS Hospital
-
-
Washington
-
Spokane, Washington, United States, 99204
- Sacred Heart Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Hospital
-
Milwaukee, Wisconsin, United States, 53215
- St. Luke's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age greater than or equal to 18 years.
- Approved by the institution's heart failure/transplant committee for VAD implantation, either as a bridge to cardiac transplantation or for destination therapy for end-stage heart failure.
- Signed informed consent, release of medical information, and HIPAA forms.
- Expectation of compliance with protocol procedures and study visit schedule.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Study Population
150 subjects with end-stage heart failure who have been scheduled to undergo device implantation with a VAD, either as a bridge to cardiac transplantation or for destination therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of suspected infections, characterized by infecting organism and location.
Time Frame: Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.
|
The primary goal is to collect information that describes infections in patients receiving LVADs.
|
Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Collect and quantify culture results for suspected infections and the secondary manifestations of infection
Time Frame: Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.
|
Bacteria normally live on our skin and in our noses.After surgery, they can infect the VAD.
We will collect cultures before and after surgery and compare these bacteria to bacteria that cause infections.Their genes will be compared to see which ones help the bacteria cause infection.
We hope this will help develop new ways to help prevent VAD infections.
|
Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.
|
Develop Guidelines to properly diagnose VAD infections
Time Frame: Up to one year following VAD implantation, time of death or transplantation, whichever comes first.
|
Information will be collected on patient's medical condition after surgery including blood tests to help determine if an infection is present.
|
Up to one year following VAD implantation, time of death or transplantation, whichever comes first.
|
Costs (direct)
Time Frame: Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.
|
The value of all resources that are consumed in the provision of an intervention or dealing with the side-effects or other current and future consequences linked to it.
|
Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.
|
Adverse Events
Time Frame: Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.
|
Since this is an observational study there will be no adverse events directly attributable to a study intervention.
However, adverse events that might potentially contribute to the risk or course of VAD-related infections will be monitored.
|
Duration of the study, up to one year following VAD implantation, time of death or transplantation, whichever comes first.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Michael Parides, PhD, Icahn School of Medicine at Mount Sinai
- Study Director: Patrice Desvigne-Nickens, National Heart, Lung, and Blood Institute (NHLBI)
- Study Chair: Yoshifumi Naka, MD, Columbia University
Publications and helpful links
General Publications
- Gordon RJ, Weinberg AD, Pagani FD, Slaughter MS, Pappas PS, Naka Y, Goldstein DJ, Dembitsky WP, Giacalone JC, Ferrante J, Ascheim DD, Moskowitz AJ, Rose EA, Gelijns AC, Lowy FD; Ventricular Assist Device Infection Study Group. Prospective, multicenter study of ventricular assist device infections. Circulation. 2013 Feb 12;127(6):691-702. doi: 10.1161/CIRCULATIONAHA.112.128132. Epub 2013 Jan 11.
- Gordon RJ, Miragaia M, Weinberg AD, Lee CJ, Rolo J, Giacalone JC, Slaughter MS, Pappas P, Naka Y, Tector AJ, de Lencastre H, Lowy FD. Staphylococcus epidermidis colonization is highly clonal across US cardiac centers. J Infect Dis. 2012 May 1;205(9):1391-8. doi: 10.1093/infdis/jis218. Epub 2012 Mar 29.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 08-1093 HP
- 5P50HL077096 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congestive Heart Failure
-
Adnan Kastrati, MDBiotronik SE & Co. KGCompleted
-
Signature Medical, Inc.WithdrawnHeart Failure,Congestive
-
Echosense Ltd.WithdrawnCongestive Heart Failure (CHF)United States
-
Corthera, Inc.(formerly BAS Medical, Inc.), a member...TerminatedCongestive Heart Failure (CHF)Russian Federation
-
Meir Medical CenterUnknown
-
Nihon KohdenTerminatedHeart Failure,CongestiveUnited States
-
ELA Medical, Inc.Approved for marketing
-
Abbott Medical DevicesCompletedCongestive Heart Failure TreatedItaly
-
Echosense Ltd.Terminated
-
Magenta Medical Ltd.TerminatedCongestive Heart Failure | Heart Failure, Congestive | Acute Heart FailureCroatia, Belgium, Serbia